Skip to main content

ORIGINAL RESEARCH article

Front. Oncol.
Sec. Neuro-Oncology and Neurosurgical Oncology
Volume 14 - 2024 | doi: 10.3389/fonc.2024.1447113
This article is part of the Research Topic Molecular and Immune Influences in the Progression of Gliomas Vol II View all 4 articles

Prognostic Significance and Gene Co-Expression Network of CD16A and FGL2 in Gliomas

Provisionally accepted
Ziwen Cao Ziwen Cao 1Xing Liu Xing Liu 2*Jun Yan Jun Yan 1*
  • 1 Beijing Institute for Brain Disorders, Capital Medical University, Beijing, Beijing Municipality, China
  • 2 Department of Neuropathology, Beijing Neurosurgical Institute, Beijing Tiantan Hospital, Capital Medical University, Beijing, China

The final, formatted version of the article will be published soon.

    The CD16A protein encoding gene FcγRIIIa (FCGR3A) and its potential ligand Fibrinogen-like protein 2 (FGL2) participate in a series of cell physiological activities on the extracellular surface.Abnormal expression of FCGR3A and FGL2 is associated with tumorigenesis. To evaluate the prognostic value of FCGR3A/FGL2 transcription expression in glioma and to explore how they affect the generation and progression of glioma, online databases are applied to analysis, such as TCGA, GEPIA, CGGA, cBioPortal, TISCH, LinkedOmics, Ivy Glioblastoma Atlas Project and Human Protein Atlas. The expression of FCGR3A/FGL2 was found to be significantly associated with clinical variables including age, tumor type, WHO grade, histology, IDH-1 mutation, and 1p19q status. FCGR3A and FGL2 had a high correlation in transcriptional expression levels. High expression of FCGR3A and FGL2 predicted a poor prognosis in primary glioma and recurrent glioma patients, especially in lower grade gliomas. Cox regression analysis indicated that high expression of FCGR3A and FGL2 were independent prognostic factors for shorter overall survival in glioma patients. FCGR3A and FGL2 and their co-expression genes were found to be involved in inflammatory activities and tumor-related signaling pathways in gene co-expression network analysis. Finally, tissue microarrays obtained from glioma patients in Tiantan hospital were used to 2 detect FCGR3A and FGL2 at the protein level. FCGR3A expression was significantly higher in high-grade gliomas than in low-grade gliomas. In conclusion, FCGR3A and FGL2 could be promising prognostic biomarkers and potential therapeutic targets of glioma patients.

    Keywords: FCGR3a, FGL2, Glioma, prognosis, Gene network

    Received: 22 Jul 2024; Accepted: 29 Oct 2024.

    Copyright: © 2024 Cao, Liu and Yan. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Xing Liu, Department of Neuropathology, Beijing Neurosurgical Institute, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
    Jun Yan, Beijing Institute for Brain Disorders, Capital Medical University, Beijing, 100069, Beijing Municipality, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.